Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

BACKGROUND AND OBJECTIVE: Gilteritinib is a novel, highly selective tyrosine kinase inhibitor approved in the USA, Canada, Europe, Brazil, Korea, and Japan for the treatment of FLT3 mutation-positive acute myeloid leukemia. This article describes the clinical pharmacokinetic profile of gilteritinib....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Pharmacokinet
Main Authors: James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Format: Artigo
Jezik:Inglês
Izdano: Springer International Publishing 2020
Teme:
Original Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7550323/
https://ncbi.nlm.nih.gov/pubmed/32304015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00888-w
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki